Financial Tearsheet

Company Overview

Recent Financial News

Date   Headline
Feb 07, 2019 Aytu BioScience Reports 71% Revenue Growth in Q2 FY19
Jan 31, 2019 Aytu BioScience to Report Fiscal Second Quarter 2019 Results and Business Update
Jan 15, 2019 Aytu BioScience Announces U.S. Field Sales Launch of Tuzistra(R) XR
Jan 10, 2019 Aytu BioScience Provides Natesto(R) Commercial Update for the Quarter Ending December 31, 2018, Reports 27% Prescription Growth and Expansion of Natesto(R) Direct Program
Dec 06, 2018 Aytu BioScience Announces Commercial Availability of Tuzistra(R) XR (codeine polistirex and chlorpheniramine polistirex) oral suspension

IR Contacts

Hayden IR

James Carbonara
1441 Broadway
Fifth Floor
New York, NY 10018
Office: (646)-755-7412
James@haydenir.com

Stock Performance

Today's Open 1.07
Volume 151,088
Day Range 1.05 - 1.11
52 Week Range 0.23 - 6.96
Bid/Ask 1.06 / 1.11
Bid/Ask Size 11,700 X 1,500
Previous Close 1.07
Market Cap 9.38 million
Shares Outstanding 8.63 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -7.172500
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Feb 07, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Nov 07, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Sep 06, 2018 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Feb 08, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Josh Disbrow, Chairman & Chief Executive Officer

Jarrett Disbrow, Chief Operating Officer

David Green, Chief Financial Officer

Board of Directors

Josh Disbrow, Chairman & Chief Executive Officer

Gary Cantrell, Director, Chair, Compensation Committee

Carl Dockery, Director, Chair, Nominating & Governance Committee

John Donofrio, Jr., Director, Chair, Audit Committee

Michael Macaluso, Director